Safia K. Rizvi

Safia K. Rizvi is a prominent figure in the biopharmaceutical industry, currently serving as a Board Member at Kermode Biotechnologies since October 2021. She has over 20 years of experience in the field, showcasing a robust background in both science and business management.

Professional Background

• Current Roles:
  • Chief Executive Officer at Cila Therapeutics (since June 2018)
  • Board Member at Kermode Biotechnologies (since October 2021)
• Previous Experience:
  • Chief Operating Officer at Caravan Biologix (August 2020 - February 2023)
  • Managing Director at The Blue Group, focusing on strategic advisory for the life sciences industry (2016 - June 2018)
  • Various leadership positions at Nestlé Skin Health and UCB, where she managed significant operations and marketing strategies across multiple regions, including the US, EU, APAC, and MENA markets.1

Education

Safia holds a Ph.D. in Chemistry/Biochemistry from the University of Oklahoma, where her dissertation focused on receptor-mediated iron transport. She also earned an MBA in Health/Health Care Management from The Wharton School.1

Achievements

• Safia has successfully launched ten products across five disease areas and has been involved in deals worth a combined $12 billion.
• She is recognized for her leadership and contributions to the field, having received accolades such as the Women of Distinction Award from the Philadelphia Business Journal and being named one of the 50 Women to Watch by 50/50 Women on Boards in 2024.12

Leadership and Advocacy

In addition to her corporate roles, Safia is an active member of Executive Women in Bio, emphasizing her commitment to advancing women in leadership within the biotechnology sector.13

Her multifaceted expertise positions her as a key player in driving innovation and growth within the biopharmaceutical landscape.